Protecting the gastrointestinal system during chemotherapy or radiation could allow patients to tolerate more aggressive treatments to attack tumors.
Ten-year-old Ellie Stewart was diagnosed with choriocarcinoma in February. Her only plans for the summer were to finish her chemotherapy treatment at N.C. Children’s Hospital. Then she received a surprise gift: tickets to attend Taylor Swift’s June 9 concert in Raleigh. Now Ellie has some memories to help carry her through.
UNC’s Brian Strahl, PhD, and Van Andel Research Institute’s Scott Rothbart, PhD, create a robust online interactive database to address science’s ‘antibody crisis’.
High school dropout, Green Beret medic who served three tours in Iraq, Special Forces medic instructor at Fort Bragg, lymphoma fighter who is free of cancer today, and future physician and researcher -- the remarkable path to medicine of rising third-year UNC medical student Eric Strand.
Graduate student Sarah Shelton reinvented herself from a dancer to a scientist. Now, she’s creating a new ultrasound technique to improve cancer diagnostics.
A freshman professor when Michael Jordan was a first-year student-athlete, Keith Burridge, PhD, has dedicated his career to elucidating the intricate structures of cells that allow cancers to metastasize.
UNC Lineberger researchers are collaborating through the ClinGen consortium to pinpoint disease-causing genetic variants.
The latest installment in the Family House Diaries video series features Dr. Tom Shea, the Director and Founder of UNC's Bone Marrow Transplant Program, and Joe and Veatrice Harris of Roanoke Rapids, North Carolina.
Nearly a year ago, thirteen-year-old Liam Canard, of Raleigh, was diagnosed with Hodgkin’s lymphoma. Although his fight against the disease goes on today, he has already won by continuing to do what he loves.
A University of North Carolina at Chapel Hill analysis published today in the journal Tobacco Control synthesized the results of 37 different experiments comparing picture-based and text warnings, finding that picture-based warnings were more effective than text warnings on 20 of 25 different outcome measures.
A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Cancer Research, the authors report that they found high levels of an enzyme in melanoma samples that they believe is a potential drug target.
The new experimental assay can help scientists find the precise locations of repair of DNA damage caused by UV radiation and common chemotherapies. The invention could lead to better cancer drugs or improvements in the potency of existing ones.
A cancer genomics study led by UNC Lineberger researchers and other scientists involved in The Cancer Genome Atlas (TCGA) project, a National Cancer Institute and National Human Genome Research Institute-backed effort to create a comprehensive atlas of the genetic changes in cancer, was selected as one of the top 10 clinical research achievements of the year.
Fifteen years ago, Nancy Raasch was diagnosed with metastatic breast cancer. Then, in 2009, came multiple myeloma. Despite these malignancies, she refuses to let cancer define her.
A UNC Lineberger-led study found that people with higher-risk melanoma containing either BRAF or NRAS gene mutations had lower survival rates.
Using human cancer cell lines, UNC scientists identified various ways that HER2-positive breast cancer tumors resist therapy, and they discovered a potential combination therapy to overcome multiple mechanisms of resistance and kill cancer cells.
Two years ago, Carmen Ward was diagnosed with a type of breast cancer called mucinous carcinoma. In her early 80s, she continues to be grateful for the life she's led and the future she has, and she points to her care at UNC Hospitals for helping her maintain a positive outlook.
UNC sequenced the RNA for 10,000 tumor samples as part of The Cancer Genome Atlas project, a National Cancer Institute and National Human Genome Research Institute backed effort to create a comprehensive atlas of the genetic changes in cancer.
Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials that will test an experimental treatment in which patients’ own immune cells are genetically engineered to fight their cancer.
Chuck Perou, PhD, professor of Genetics and Pathology at UNC Lineberger Comprehensive Cancer Center, was recently interviewed by Oncology Times for the publication's "Three Questions" series.